MedTrace Logo

Investigation of Antidepressant Efficacy of Oral Ketamine Treatment

NCT02992496 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-09-03

No results posted yet for this study

Summary

The purpose of this double-blind, controlled, randomized study is to investigate the antidepressant efficacy of oral ketamine treatment in patients suffering from a major depressive episode.

Conditions

  • Major Depressive Episode

Interventions

DRUG

Ketamine

1mg/kg, 6 applications over 2 weeks

DRUG

Midazolam Hydrochloride

0.03mg/kg, 6 applications over 2 weeks

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-24
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02992496 on ClinicalTrials.gov